Drugs & Targets After two CRLs, FDA advisory committee votes in favor of Replimune’s melanoma drug July 31, 2026Vol.52 No.30
Drugs & Targets EMA CHMP recommends approval for biosimilar Denosumab Ascend and Nylaspeg, recommends against Tacquell July 31, 2026Vol.52 No.30
Drugs & Targets FDA approves Jideytro for previously treated ROS1-positive non-small cell lung cancer July 24, 2026Vol.52 No.29
Drugs & Targets FDA grants priority review for Talzenna + Xtandi combo in earlier prostate cancer July 24, 2026Vol.52 No.29
Drugs & Targets EMA approves phase III clinical study of Alpha1H bladder cancer therapy July 24, 2026Vol.52 No.29
Drugs & Targets FDA approves Padcev + Keytruda for muscle-invasive bladder cancer regardless of cisplatin eligibility July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves Revtorpyk for HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves Sarclisa Escena for subcutaneous injection for multiple indications in MM July 17, 2026Vol.52 No.28
Drugs & Targets FDA approves companion diagnostic for Opdivo for ESCC and GEJ, gastric, and esophageal adenocarcinoma July 17, 2026Vol.52 No.28
Drugs & Targets FDA issues CRL for rivoceranib + camrelizumab as a first-line treatment for unresectable or metastatic HCC July 17, 2026Vol.52 No.28
